Skip to content

Study · Not a test of the peptide alone · 2017

3 results

One-week in vivo sustained release of a peptide formulated into in situ forming implants.

Parent M, Clarot I, Gibot S, Derive M, Maincent P, Leroy P, Boudier A

International journal of pharmaceutics20 Feb 2017Cited by 11 (Europe PMC)

PMID28232200 (opens in a new tab)DOI10.1016/j.ijpharm.2017.02.046 (opens in a new tab)PepBankPUB-28232200
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Nangibotide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Nangibotide.

  1. 01AnimalNot a test of Nangibotide aloneAnimal study (in vivo)Pharmacokinetics

    In Wistar rats, a single LR12 implant formulation administration produced sustained release for 7 days.

    In plain wordsIn rats, a single LR12 implant formulation administration sustained release for 7 days.

    Peptide
    Nangibotide
    Outcome
    Not applicableSustained release
    Study

    ratn: not reported in source

    Wistar rats
    Outcome group
    Pharmacokinetics · Pharmacology

    Measurements

    Sustained release duration
    7 days
    single administration

    Source sentences

    Summary
    In vivo, a 7-day sustained release was demonstrated after administrating the formulation once; bioavailability was improved by protecting the peptide against the degradation identified as a dimerization through disulfide bond formation.
    1 context sentence
    Summary · context
    In order to protect peptide from degrading and to prolong its release, in situ implants based on biocompatible biodegradable polymers were prepared and both in vitro and in vivo releases were evaluated after subcutaneous administration to Wistar rats.

    In this study, Nangibotide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Nangibotide.

  2. 02AnimalNot a test of Nangibotide aloneAnimal study (in vivo)Pharmacokinetics

    In Wistar rats, the LR12 implant formulation improved bioavailability by protecting the peptide against degradation through dimerization.

    In plain wordsIn rats, the LR12 implant formulation improved bioavailability by protecting the peptide against degradation.

    Peptide
    Nangibotide
    Outcome
    IncreaseBioavailability
    Study

    ratn: not reported in source

    Wistar rats
    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    In vivo, a 7-day sustained release was demonstrated after administrating the formulation once; bioavailability was improved by protecting the peptide against the degradation identified as a dimerization through disulfide bond formation.
    1 context sentence
    Summary · context
    In order to protect peptide from degrading and to prolong its release, in situ implants based on biocompatible biodegradable polymers were prepared and both in vitro and in vivo releases were evaluated after subcutaneous administration to Wistar rats.

    In this study, Nangibotide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Nangibotide.

  3. 03LabNot a test of Nangibotide aloneIn vitro (cell-free)Pharmacokinetics

    In vitro, LR12 polymer implants produced progressive and complete release in 3 weeks.

    In plain wordsIn lab tests, LR12 polymer implants released the peptide progressively and completely in 3 weeks.

    Peptide
    Nangibotide
    Outcome
    Not applicableIn vitro release
    Study

    n: not reported in source

    In situ polymer implants
    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    A progressive and complete release was obtained in vitro in 3 weeks.
    1 context sentence
    Summary · context
    In order to protect peptide from degrading and to prolong its release, in situ implants based on biocompatible biodegradable polymers were prepared and both in vitro and in vivo releases were evaluated after subcutaneous administration to Wistar rats.

    In this study, Nangibotide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Nangibotide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.